<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Rising drug resistance and public funding drive demand for AI, cloud software, managed surveillance, molecular diagnostics and portable sequencing, especially in Asia-Pacific and LMICs.Dublin, Aug. 25, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/5986179/antimicrobial-resistance-surveillance-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kwx897&amp;utm_campaign=2336314+-+Antimicrobial+Resistance+Surveillance+Market+(2026-2031)+-+Rising+Prevalence+of+Drug-Resistant+Infections+to+Drive+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="Antimicrobial Resistance Surveillance - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Antimicrobial Resistance Surveillance - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. Antimicrobial Resistance Surveillance Market to Reach USD 8.66 Billion by 2031 as Drug-Resistant Infections Accelerate The global antimicrobial resistance surveillance market is projected to grow from USD 6.24 billion in 2025 to USD 6.59 billion in 2026, reaching USD 8.66 billion by 2031. The market is forecast to expand at a compound annual growth rate of 5.62% from 2026 to 2031, driven by the rising prevalence of drug-resistant infections, increased government funding, and wider adoption of artificial intelligence, molecular diagnostics, and genomic sequencing. Rising Drug Resistance Drives Demand for Advanced Surveillance High antimicrobial resistance rates across all World Health Organization regions continue to increase demand for faster and more coordinated surveillance. Hypervirulent carbapenem-resistant Klebsiella pneumoniae sequence type 23 has been documented in 16 countries, affecting both healthy and immunocompromised individuals and prompting health authorities to strengthen monitoring capabilities. In Southeast Asia, carbapenem-resistant E. coli and Klebsiella have been reported in eight and nine of 11 countries, respectively, with Indonesia, the Philippines, Thailand, and Vietnam experiencing a particularly heavy burden. The WHO forecasts that antimicrobial resistance could contribute to 5.2 million deaths in the Western Pacific by 2030 and generate economic losses of USD 148 billion. These risks are compelling healthcare systems to invest in integrated antimicrobial resistance surveillance platforms. Government Funding Supports Genomic and Real-Time Monitoring Public-sector initiatives are accelerating surveillance infrastructure development. In 2024, the International Pathogen Surveillance Network introduced a USD 4 million catalytic fund to strengthen genomic monitoring in low- and middle-income countries. The United Kingdom also expanded its real-time sequencing program with Oxford Nanopore Technologies from 10 to 30 National Health Service sites. In the United States, the draft PASTEUR Act proposes USD 6 billion for antimicrobial innovation and surveillance improvements. The Biomedical Advanced Research and Development Authority is also supporting artificial intelligence-based diagnostic development through partnerships with Pattern Bioscience and BugSeq. Meanwhile, the Food and Agriculture Organization's antimicrobial resistance multi-partner trust fund is supporting integrated surveillance programs across 10 countries through 2030. High Implementation Costs Remain a Market Challenge Despite strong demand, capital and operating costs continue to limit adoption, particularly in resource-constrained settings. Whole-genome sequencing platforms can require initial investments exceeding USD 500,000, while annual reagent and maintenance costs may approach USD 200,000 per site. Networked surveillance programs add further expenses through standardized laboratory protocols, data warehouses, quality-control systems, and secure information exchange. To reduce these barriers, the WHO is offering catalytic grants ranging from USD 50,000 to USD 250,000 for qualifying projects in low- and middle-income countries. Developers are also advancing lower-cost sensors, portable sequencing devices, and cloud-based analytics. Other factors influencing market development include antibiotic misuse, the emergence of multidrug-resistant pathogens, growing use of predictive analytics, and shortages of skilled microbiologists and bioinformaticians. Surveillance Software and AI Platforms Gain Momentum Surveillance software accounted for 41.63% of market revenue in 2025, reflecting its central role in coordinating data across hospitals, laboratories, and public health agencies. Surveillance services are projected to grow at a 6.08% CAGR as healthcare providers increasingly outsource analytics, regulatory reporting, and compliance management. Subscription-based platforms enable vendors to deliver continuous algorithm updates, outbreak alerts, stewardship tools, and regulatory dashboards. These cloud-based solutions also give smaller hospitals access to advanced surveillance capabilities without requiring extensive local information technology infrastructure. bioMerieux's acquisition of LUMED demonstrates the industry's shift toward integrated diagnostic and antimicrobial stewardship offerings. Molecular diagnostics represented 38.55% of 2025 revenue, supported by demand for rapid gene-based detection through polymerase chain reaction and next-generation sequencing. AI and data analytics platforms are expected to record the fastest technology growth, at a 6.15% CAGR. By combining clinical, genomic, and epidemiological data, these platforms can support resistance forecasting, outbreak detection, and treatment decisions. Portable sequencers, including Oxford Nanopore Technologies' MinION, are also enabling real-time data processing through cloud-connected AI systems. Whole-genome sequencing remains important for cluster investigation, while integrated molecular and predictive platforms are gaining traction across clinical and public health applications. Regional Antimicrobial Resistance Surveillance Market Outlook North America led the market with a 42.15% revenue share in 2025. The region benefits from USD 650 million in project funding through the CDC Antimicrobial Resistance Solutions Initiative, supportive regulatory policies, and collaboration among the CDC, BARDA, healthcare providers, and diagnostic technology companies. Asia-Pacific is forecast to be the fastest-growing regional market, expanding at a 6.41% CAGR. China continues to develop national surveillance networks integrating hospital and agricultural data, while India's i-AMRSS open-source platform connects more than 100 sentinel sites. Singapore's One Health-aligned roadmap also combines human, animal, and environmental surveillance data. Europe is experiencing steady adoption through coordinated surveillance frameworks and cross-border reporting systems. Latin America, the Middle East, and Africa are also gaining momentum as participation in the WHO Global Antimicrobial Resistance and Use Surveillance System expands and international grants support early-stage network deployment. Portable diagnostics, affordable sequencing, and cloud-based AI platforms are expected to help these regions overcome infrastructure constraints and broaden access to antimicrobial resistance surveillance. Key Topics Covered: 1 Introduction 1.1 Study Assumptions &amp; Market Definition 1.2 Scope of the Study 2 Research Methodology 3 Executive Summary 4 Market Landscape 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Prevalence of Drug-Resistant Infections 4.2.2 Government Initiatives &amp; Funding for AMR Programmes 4.2.3 Emergence Of Multi-Drug Resistance from Antibiotic Misuse 4.2.4 Accreditation-Driven Uptake of Hospital Infection-Tracking Tools 4.2.5 AI-Driven Predictive Analytics Adoption in AMR Platforms 4.2.6 Portable Genomic Sequencers Enabling LMIC Field Surveillance 4.3 Market Restraints 4.3.1 High Capital &amp; Operating Cost of AMR Surveillance Systems 4.3.2 Shortage Of Skilled Microbiologists &amp; Bioinformaticians 4.3.3 Cross-Border Genomic-Data-Sharing Ethical Barriers 4.3.4 Lower Awareness in Developing Regions 4.4 Regulatory Landscape 4.5 Technological Outlook 4.6 Porters Five Forces Analysis 4.6.1 Bargaining Power of Suppliers 4.6.2 Bargaining Power of Buyers/Consumers 4.6.3 Threat of New Entrants 4.6.4 Threat of Substitute Products 4.6.5 Intensity of Competitive Rivalry 5 Market Size &amp; Growth Forecasts (Value, USD) 5.1 By Solution 5.1.1 Kits 5.1.2 Systems 5.1.3 Surveillance Software 5.1.4 Surveillance Services 5.2 By Technology 5.2.1 Culture-based Methods 5.2.2 Molecular Diagnostics 5.2.3 Whole-Genome Sequencing 5.2.4 AI and Data-Analytics Platforms 5.2.5 Others 5.3 By Application 5.3.1 Clinical Diagnostics 5.3.2 Public-Health Surveillance 5.3.3 Antimicrobial Stewardship Programmes 5.3.4 Pharma &amp; Biotech R&amp;D 5.3.5 Others 5.4 By End-User 5.4.1 Hospitals and Clinics 5.4.2 Diagnostic Laboratories 5.4.3 Other End-Users 5.5 By Geography 5.5.1 North America 5.5.1.1 United States 5.5.1.2 Canada 5.5.1.3 Mexico 5.5.2 Europe 5.5.2.1 Germany 5.5.2.2 United Kingdom 5.5.2.3 France 5.5.2.4 Italy 5.5.2.5 Spain 5.5.2.6 Rest of Europe 5.5.3 Asia-Pacific 5.5.3.1 China 5.5.3.2 Japan 5.5.3.3 India 5.5.3.4 Australia 5.5.3.5 South Korea 5.5.3.6 Rest of Asia-Pacific 5.5.4 Middle East and Africa 5.5.4.1 GCC 5.5.4.2 South Africa 5.5.4.3 Rest of Middle East and Africa 5.5.5 South America 5.5.5.1 Brazil 5.5.5.2 Argentina 5.5.5.3 Rest of South America 6 Competitive Landscape 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products &amp; Services, Recent Developments) 6.3.1 Accelerate Diagnostics 6.3.2 Becton, Dickinson &amp; Co. 6.3.3 bioMerieux SA 6.3.4 Bruker Corp. 6.3.5 Cepheid (Danaher) 6.3.6 DiaSorin SpA 6.3.7 Illumina Inc. 6.3.8 Liofilchem Srl 6.3.9 Merck KGaA 6.3.10 Oxford Nanopore Technologies 6.3.11 Pfizer Inc. 6.3.12 Qiagen NV 6.3.13 Roche Diagnostics 6.3.14 Thermo Fisher Scientific 6.3.15 T2 Biosystems 6.3.16 Luminex (Diasorin) 6.3.17 Abbott Laboratories 6.3.18 Seegene Inc. 6.3.19 OpGen Inc. 6.3.20 SyntBioLab Inc. 7 Market Opportunities &amp; Future Outlook 7.1 White-space &amp; Unmet-need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/5986179/antimicrobial-resistance-surveillance-market?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kwx897&amp;utm_campaign=2336314+-+Antimicrobial+Resistance+Surveillance+Market+(2026-2031)+-+Rising+Prevalence+of+Drug-Resistant+Infections+to+Drive+Growth&amp;utm_exec=clshmsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/9nicdp</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/MmVkMDM4M2QtNjExZi00YTk1LWExOGQtODQ5YTNlMzJhNjBhLTEwMjY3MzctMjAyNi0wOC0yNS1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Antimicrobial Resistance Surveillance Market (2026-2031) - Rising Prevalence of Drug-Resistant Infections to Drive Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn